Companies / Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc.

Nasdaq: LXEOCIK 1907108NEW YORK, NY

Financials · FY2023

Revenue$654.0K
Net income$-99.96M
Total debt—
Cash$92.83M
Diluted EPS$-1.86
Shares outstanding82.0M

Ownership

82.0M shares outstanding · as of Aug 10, 2026
0.81%Insiders
Ownership
Insiders0.81%665,661
10%+ / strategic11.26%9,240,589
Institutions84.62%69,427,913
Public float3.31%2,712,092

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Townsend Richard NolanCEOChief Executive Officer · Director
0.48%395,106
Otero Jose ManuelChief Operating Officer
0.16%131,390
Tamayo Louis EdwardChief Financial Officer
0.11%89,665
Bhalla Narinder PalChief Medical Officer
0.06%49,500
Cholmondeley Paula HDirector
——
Diaz Reinaldo MDirector
——

Institutional holders 146

View all →
HolderValue% of shares
Paradigm BioCapital Advisors LP$47.30M5.81%
Vestal Point Capital, LP$44.44M5.45%
Frazier Life Sciences Management, L.P.$43.94M5.39%
Vanguard Group Inc$38.67M4.75%
Citadel Advisors LLC$37.48M4.60%
Avoro Capital Advisors LLC$32.77M4.02%
Affinity Asset Advisors, LLC$31.78M3.90%
Woodline Partners LP$31.75M3.90%
RA Capital Management, L.P.$28.70M6.09%
Janus Henderson Group PLC$28.51M6.07%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 18, 2026Townsend Richard Nolan
CEO
SellCommon Stock$64.9K-10K
-2.53%
392,483
0.48% of shares
low
Feb 18, 2026Otero Jose Manuel
Executive
SellCommon Stock$19.3K-3K
-2.35%
125,460
0.15% of shares
low
Mar 13, 2026Otero Jose Manuel
Executive
GrantCommon Stock$15.7K+6K
+4.73%
131,390
0.16% of shares
low
Mar 13, 2026Townsend Richard Nolan
CEO
GrantCommon Stock$6.9K+3K
+0.67%
395,106
0.48% of shares
low
Nov 18, 2025Otero Jose Manuel
Executive
SellCommon Stock$6.7K-721
-1.12%
63,476
0.08% of shares
low
Feb 13, 2026Bhalla Narinder Pal
Executive
GrantCommon Stock$0+50K
49,500
0.06% of shares
low
Feb 4, 2026Tamayo Louis Edward
Executive
GrantCommon Stock$0+45K
+99.26%
89,665
0.11% of shares
low
Feb 4, 2026Otero Jose Manuel
Executive
GrantCommon Stock$0+65K
+102.40%
128,476
0.16% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
State Street CorporationPassive13G—4,354,775—
Vanguard Group IncPassive13G/A—0—
Vanguard Group IncPassive13G—3,894,310—
Balyasny Asset Management L.P.Passive13G/A———
Citadel Advisors LLCPassive13G/A———
Affinity Asset Advisors, LLCPassive13G/A———
Paradigm BioCapital Advisors LPPassive13G/A———
Frazier Life Sciences Public Fund, L.P.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
LXEO——52886X107—